SCHEMBL702234

SCHEMBL702234

CN(C)c1ccc(-c2ccc(C=C3C(=O)Nc4ccc(Cl)cc43)o2)cn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
POLB P06746 1/20 0.52
GAA P10253 1/20 0.52
MAPT P10636 1/20 0.52
PKM P14618 1/20 0.52
PPARG P37231 1/20 0.52
NCOA2 Q15596 1/20 0.52
NCOA1 Q15788 1/20 0.52
PIM1 P11309 7/20 0.49
PIM2 Q9P1W9 7/20 0.49
FLT3 P36888 2/20 0.49
PIM3 Q86V86 1/20 0.49
RPS6KA3 P51812 1/20 0.48
MITF O75030 1/20 0.48
RET P07949 2/20 0.47
SIRT2 Q8IXJ6 1/20 0.47
PTPN1 P18031 4/20 0.46
PTPN2 P17706 1/20 0.46
LRRK2 Q5S007 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL702233 1.00 MEN1 (0.52) MEN1KMT2APOLBGAAMAPT
SCHEMBL10091758 1.00 MEN1 (0.52) MEN1KMT2APOLBGAAMAPT
SCHEMBL10091728 0.81 PIM1 (0.59) MEN1KMT2APOLBGAAMAPT
SCHEMBL701129 0.80 PIM1 (0.59) MEN1KMT2APOLBGAAMAPT
SCHEMBL701130 0.80 PIM1 (0.59) MEN1KMT2APOLBGAAMAPT
SCHEMBL10091759 0.80 PIM1 (0.59) MEN1KMT2APOLBGAAMAPT
SCHEMBL10091725 0.77 MEN1 (0.61) MEN1KMT2APOLBGAAMAPT
SCHEMBL10091732 0.76 MEN1 (0.85) MEN1KMT2APOLBGAAMAPT
SCHEMBL10091727 0.76 MEN1 (0.60) MEN1KMT2APOLBGAAMAPT
SCHEMBL703013 0.76 MEN1 (0.85) MEN1KMT2APOLBGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120190669-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2012-07-26 US disclosed
US-8124649-B2 Oxindole compounds CYLENE PHARMACEUTICALS, INC. (US) 2012-02-28 US disclosed
EP-2307421-A1 OXINDOLE COMPOUNDS Cylene Pharmaceuticals, Inc. (US) 2011-04-13 EP disclosed
US-20100041635-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. 2010-02-18 US disclosed
WO-2010002933-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041635-A1 OXINDOLE COMPOUNDS FLT3, PIM1, PIM2 MEN1 3039/4885KMT2A 1375/4885POLB 2906/4885
US-20120190669-A1 OXINDOLE COMPOUNDS FLT3, PIM1, PIM2 MEN1 3039/4885KMT2A 1375/4885POLB 2906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.